SLC4A2 and primary biliary cholangitis: Mir-506 targets Cl−/HCO3− anion exchanger 2 (AE2/SLC4A2) and type III inositol 1,4,5-trisphosphate receptor (InsP3R3) in cholangiocytes and can thus develop into a therapeutic target for PBC [250].